Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-859 first-line pembrolizumab plus chemotherapy in HER2-negative gastric or gastroesophageal junction adenocarcinoma
MOH_2022-12-07_003636Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Aug 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma comparing Pembrolizumab with chemotherapy with Placebo with chemotherapy (2 arms). Started Aug 2018; status: active, not recruiting.
02
Drugs
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on MOH_2022-12-07_003636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-12-07_003636.